Pharmacokinetics comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-26. Numbers and descriptions here follow the published literature rather than marketing material.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
| Property | Value | Notes |
|---|---|---|
| Primary target | Melanocortin receptors | Mainly the MC4R subtype |
| Route of administration | Injection | Typically subcutaneous |
| Time to peak | About 60 minutes | After subcutaneous dosing |
| Elimination half-life | Roughly 2 to 3 hours | Values vary across reports |
| Metabolic pathway | Peptidase hydrolysis | Cleared by the kidneys |
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
US and Canada: Pentacarinat 300 injection powder 300 mg vial (Avantis Pharma Inc - Canada) Pentam 300 (APP Pharmaceuticals LLC - US) Pentamidine isethionate 300 mg for injection (David Bull Laboratories LTD - Canada, Hospira Healthcare Corporation - Canada) International Brands: Pentamidine isethionate (Abbott) Pentacarinat (Sanofi-Aventis) Pentacrinat (Abbott) Pentam (Abbott) Pneumopent
Is also mentioned the propaganda campaigns carried out by the Bolivian press with an anti-Peruvian tendency when it came to border demarcations during the 20th century, for which the Ministry of Foreign Affairs of Peru had to intervene to put pressure on the Bolivian Foreign Ministry in 1938 against tendentious articles that they made Bolivian newspapers in an attempt to challenge the Demarcation Protocol of the province of Copacabana; Bolivian politicians were reportedly involved in this anti-Peruvian campaign, such as the Omasuyos deputy, Eguino Zaballa, who personally participated in the drafting of some articles on the alleged damages that Bolivia would suffer after the signing of the protocol with Peru. In February 1975, meeting in Charaña, Hugo Banzer and Augusto Pinochet issued a joint declaration that led to the Chilean proposal to give Bolivia a maritime corridor north of Arica, which was impossible while the 1929 Treaty was in force, according to the which Peru has restricted sovereignty and recognized easements over Arica, and must be consulted before any possible change in the sovereignty of the territory. It came to be suspected that this was the rapprochement of a possible anti-Peruvian axis between Chile and Bolivia against another potential military alliance between Peru and Argentina during the Cold War. With the passage of time, the distinction between pro-Peruvians and pro-Chileans has largely disappeared. Chile now has both Arica and Antofagasta, so Bolivian popular anger is more often directed against Chile.
Arizona Medical Training Institute (AMTI) is a private, vocational healthcare institute located in Mesa, Arizona. They provide entry-level medical training for students seeking careers in nursing, clinical laboratory science and the assisted living career fields.
Sources: en.wikipedia.org
== Clinical significance == Mutations in this gene are associated with type II Stickler syndrome and with Marshall syndrome. Stickler syndrome, type II is an autosomal dominant condition caused by a mutation in the COL11A1 gene. Features of Stickler syndrome type II include: sensorineural hearing loss, facial features (flat facial profile, anteverted nares, micrognathia), cleft palate, visual disturbances (type 2 vitreous anomaly, childhood-onset myopia, glaucoma, cataracts and retinal detachment), spondyloepiphyseal dysplasia, and arthropathy.
246Cm(12C,xn)258−xNo (4,5) This reaction was studied in 1958 by scientists at the LBNL using a 5% 246Cm curium target. They were able to measure 7.43 MeV decays from250Fm, associated with a 3 s 254No parent activity, resulting from the 4n channel. The 3 s activity was later reassigned to 252No, resulting from reaction with the predominant 244Cm component in the target. It could however not be proved that it was not due to the contaminant250mFm, unknown at the time. Later work in 1959 produced 8.3 MeV alpha particles with a half-life of 3 s and a 30% SF branch. This was initially assigned to 254No and later reassigned to 252No, resulting from reaction with the 244Cm component in the target. The reaction was restudied in 1967 and activities assigned to 254No and 253No were detected.
=== Traditional Chinese medicine === Within traditional Chinese medicine E. sinensis was historically used to treat a variety of ailments, such as bruises, fractures, amenorrhea, postpartum blood stasis, and used as a pain reliever. Tubiechong could be prepared in different ways depending on what was being treated, preparation methods include, grinding, frying, water extraction, and rice wine extraction. The most common method being water or rice wine extraction. Only the females are used in medicine. There are claims by TCM physicians that Tubiechong can reduce and treat tumors, via actions on blood vessels. The apparent effect on the blood vessels is why it was prescribed for the ailments it was (and still is).
==== Opium ==== Liu reportedly called opium cultivation the "lifeline" of the 24th Army and derived much of his income from the drug, which was traded and later cultivated on a massive scale. The opium business became extremely profitable after 1936 when the central government started aggressively suppressing production within the Sichuan basin, making opium grown by the Yi in the Xikang highlands extremely profitable. Lawson went as far as to conclude that the Kuomintang's anti-opium campaign was arguably "another form of assistance that the national government granted Liu Wenhui". A similar period of suppression in the lowlands coinciding with an opium boom in the highlands was also documented from 1906 to 1911 under the Qing dynasty. Cultivation of opium in Kham began after 1936, spreading to Liu's territories around the early 1940s. Liu Wenhui profited greatly from this illegal trade, and was able to fund his military and economic projects through opium sales. In 1940, he was alleged to have struck a deal with the Yunnanese governor Long Yun that let tariffed opium from Yunnan pass through Xikang en route to Sichuan. Later, this trade would decline as Xikang became a major opium producer in its own right. Historians including Lawson have so far been unable to place an exact amount on the income that Xikang gained from opium; only that it was probably at least as much as the subsidy Xikang received from the central government.
Sources: en.wikipedia.org
Nicomorphine (Vilan, Subellan, Gevilan, MorZet) is the 3,6-dinicotinate ester of morphine. It is a strong opioid agonist analgesic two to three times as potent as morphine with a side effect profile similar to that of dihydromorphine, morphine, and diamorphine. Nicomorphine was first synthesized in 1904 and was patented as Vilan by Lannacher Heilmittel G.m.b.H. of Austria in 1957.
== Organization == Americold has more than 245 locations worldwide. It is a publicly traded REIT focused on temperature-controlled warehouses. Americold owns and operates a quarry in Carthage Underground both for the excavated stone and uses the caverns and refrigerated storage chambers.
=== Anti-mutagenic === In one study, bemethyl was shown to prevent the mutagenic effect of white asbestos in mice and in cultured human whole blood. A study using mice showed bemethyl to reduce mutation induced by certain mutagenic drugs. Another study using cells from human donors showed Bemethyl to be anticlastogenic (able to minimize chromosome breakages).
Sources: en.wikipedia.org
It primarily activates specific subtypes in the melanocortin receptor family. These receptors are G protein-coupled and mediate signaling mainly within the central nervous system.
It activates pigmentation-related receptors more weakly. This selectivity is thought to alter its side effect profile.
Injection is the most common route. Nasal administration has been studied as well, though absorption varies considerably.
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.